Epidemiologie - France Portal | Health Databases

Home

Catalogue

Catalogue
ARCHIVES

Covid-19

Resources

Lexicon
Legal notices

Useful links

General links
Covid-19 links

Login in to your account

Email address Password

You do not have an account yet ? Sign up !

You have forgotten your password ?

Portail Epidémiologique

ITMO public health Aviesan

Aviesan

Archives

Search with one or more keywords

All records French records only English records only

This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.

xml

Export to XML

Please choose the format :

pdf

Export to PDF

Which version do you want to export ?

Download full content

Download light content

csv

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

ARCHIVES : 309 forms

Sorting of results :

ABSINTHE - Observational study of the therapeutic strategy in the management of acute sinusitis in primary care

Head : Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Version 2

91

Last update : 09/05/2017

ARCHIVE

ABSINTHE - Observational study of the therapeutic strategy in the management of acute sinusitis in primary care

Head : Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Main objective

The study objectives were to describe the management of acute sinusitis in real-life conditions of prescription and to evaluate the effectiveness of the initial therapeutic strategy.

Inclusion criteria

Patient consulting for acute sinusitis diagnosed according to criteria of the practitioner; Patient without a previous episode of acute sinusitis during the two months preceding diagnosis; Patient aged 18 years and over; Patient agreeing to participate in the study; Patient not included in a clinical trial (Huriet-Sérusclat); Patient who may be followed for two months; Patient showing no severe active disease (life-threatening in the next three months).

Last update : 09/05/2017

B009 - Follow-up study of patients treated with drotrecogin alfa (activated) (Xigris®) in France

Head : Laboratoire , Eli Lilly France

Version 1

92

Last update : 01/01/2019

ARCHIVE

B009 - Follow-up study of patients treated with drotrecogin alfa (activated) (Xigris®) in France

Head : Laboratoire , Eli Lilly France

Main objective

Primary objective: evaluate 1-month mortality (at 28 days and 31 days) of patients treated with drotrecogin alpha (activated) in intensive care forsevere sepsis and describe causes of death.
Secondary objectives: characteristics of patients and conditions of use.

Inclusion criteria

All adult patients treated with drotrecogin alpha (activated) in France in the course of routine care in intensive care services.

Last update : 01/01/2019

ESCALE - Case-Control Study on Childhood Cancers

Head : CLAVEL Jacqueline, UMR-S 1153 Equipe 7 / Épidémiologie des cancers de l'Enfant

Version 1

93

Last update : 09/05/2017

ARCHIVE

ESCALE - Case-Control Study on Childhood Cancers

Head : CLAVEL Jacqueline, UMR-S 1153 Equipe 7 / Épidémiologie des cancers de l'Enfant

Main objective

To investigate the influence of the following on childhood cancer risk: pregnancy outcome, child's characteristics at birth, child's environment in utero or during childhood, parents' profession and lifestyle, successive domicile communities, family history of cancer, birth defects, or autoimmune diseases. To identify genetic predispositions capable of modulating the function of these factors, including polymorphisms in genes involved in the transport and metabolism of xenobiotics, DNA repair, immune response, or in embryonic development and cell differentiation. To investigate the interactions between these polymorphisms and environmental factors.

Inclusion criteria

- Men or women - under 15 years old

Last update : 09/05/2017

SIRS - Health, Inequalities and Social Ruptures

Head : Chauvin Pierre, UMRS 707, equipe ds3 - UPMC

Version 3

94

Last update : 01/01/2019

ARCHIVE

SIRS - Health, Inequalities and Social Ruptures

Head : Chauvin Pierre, UMRS 707, equipe ds3 - UPMC

Main objective

General objective: to investigate the impact of living conditions and social integration on health and health care usage. Secondary objective: to investigate territorial factors (social, urban and available services) in relation to health an health care usage.

Inclusion criteria

Voluntary French-speaking adults

Last update : 01/01/2019

SurvSein - Study on long-term iatrogenic effects for women treated for breast cancer between 1954 and 1985 at the Institut Gustave Roussy

Head : De Vathaire Florent, U1018 CESP équipe 3
Rubino Carole, U1018 CESP équipe 3

Version 2

95

Last update : 09/05/2017

ARCHIVE

SurvSein - Study on long-term iatrogenic effects for women treated for breast cancer between 1954 and 1985 at the Institut Gustave Roussy

Head : De Vathaire Florent, U1018 CESP équipe 3
Rubino Carole, U1018 CESP équipe 3

Main objective

SurvSein is a prospective and retrospective cohort study of women treated for breast cancer between 1954 and 1983 at the Institut Gustave Roussy in order to measure the iatrogenic effects of long-term treatment.

Inclusion criteria

Subjects of female gender Women aged 18 or over Women treated for breast cancer

Last update : 09/05/2017

DEFI - Determination of epidemiology of fibromyalgia

Head : Millet Véronique, Pfizer

Version 1

96

Last update : 01/01/2019

ARCHIVE

DEFI - Determination of epidemiology of fibromyalgia

Head : Millet Véronique, Pfizer

Main objective

Main:
- Evaluate the prevalence of fibromyalgia in the general population, in five ""French regions"", by identifying:
• in a first step, by telephone, potential or known fibromyalgia patients,
• then in a second step, from among these patients, those that have fibromyalgia validated by a rheumatologist.
Secondary:
- Describe the characteristics of the patients with a diagnosis of fibromyalgia validated by a rheumatologist.
- Describe the characteristics of patients for whom this diagnosis has not been validated by the rheumatologist.
- Compare the characteristics of these two groups of patients to one another and each of them with the characteristics of the general population of the study.

Inclusion criteria

- Patients aged 18 years or older.
- Patients deemed apt to answer the questions.
- Randomly selected patients who accept to participate in the survey (in the event of a refusal, the selected person was not replaced within the home or in the study)."

Last update : 01/01/2019

Previous
1
...
10
11
12
13
14
15
16
17
18
19
20
21
22
...
52
Next

Please wait...

ABOUT

Help about your workspace

CATALOG

RESOURCES

USEFUL LINKS

This site complies with the HONcode standard for trustworthy health information:
verify here.

8 rue de la Croix Jarry

75013 Paris

Phone : +33 1 44 23 67 47

portail-epidemiologie@inserm.fr

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

XXX

View Edit Create here